Yet another blow to Merck’s cancer hopeful

GSK-partnered Merck is throwing in the towel for a Phase II trial of its immunotherapy contender bintrafusp alfa after disappointing results.

Read more

Beckley Psytech: €68m for psychedelic meds

UK-based start-up Beckley Psytech has completed an upsized Series B financing, raising €68m (US$80m). Proceeds will go towards the company’s pipeline of psychedelic compounds dedicated to addressing neurological and psychiatric disorders.

Read more

ERS Genomics and Cellular Engineering Technologies collaborating

ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.

Read more

Boehringer walks away from CureVac deal

Setback for CureVac: Boehringer Ingelheim halts a 7-year-old €500m lung cancer collaboration with the Tübingen-based biopharmaceutical company.

Read more

New vaccine trial targets Covid variants

Vaccine maker Valneva SE announced the initiation of a further Phase III trial for its COVID-19 vaccine candidate VLA2001.

Read more

Visus Therapeutics cashes in €20m from LSP

Visus Therapeutics has baged a €20m stock financing to advance development of Brimochol for presbyopia 

Read more

Protein may help control cancer cells

The protein eIF4A3 may hold the key for future cancer treatments, Karolinska researchers find.

Read more

British drug developer Mission Therapeutics plc earns $20m milestone

British drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration.

Read more

Bayer takes over Vividion

The big pharma company is shelling out US$1.5bn in the acquisition of US screening specialist Vividion Therapeutics.

Read more